NCT05227703: A reported trial by AbbVie
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05227703 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 5, 2022 |
| Completion date | Aug. 15, 2024 |
| Required reporting date | Aug. 15, 2027, midnight |
| Actual reporting date | Sept. 5, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |